This interview with a US-based key opinion leader (KOL) offers insights into current treatment practices, prescribing behaviors, and late-phase pipeline therapies in Small Cell Lung Cancer (SCLC). The discussion covers disease staging, diagnostic approaches, first- and second-line treatment selection, and the evolving role of immunotherapy and antibody-drug conjugates (ADCs) in the SCLC treatment landscape. Additional topics include patient eligibility for emerging therapies, treatment sequencing in the relapsed/refractory setting, unmet needs, and the potential impact of novel pipeline agents.

The standard of care for extensive-stage SCLC has evolved substantially with the incorporation of immune checkpoint inhibitors alongside platinum-etoposide chemotherapy. The expert emphasized a strong preference for atezolizumab as the first-line IO backbone and highlighted tarlatamab as the preferred second-line option for eligible patients, citing Phase 3 DeLLphi-304 data. The discussion also addressed the competitive positioning of multiple ADCs entering late-stage development, the sequencing challenge they present, and areas of greatest unmet need including elderly and poor performance status patients.

This interview was conducted on April 24, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.